Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs. Ysios Capital participates in the round

by Ysios Capital

Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C finan...

Read more

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

The financing was led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. Since its founding, ...

Read more

OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If...

Read more

CorWave Raises $17.1 Million in Series B Financing

by Ysios Capital

CorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing share...

Read more

Parkinson’s disease: Prexton Therapeutics, participated by Ysios Capital, completes phase 1 clinical trial

by Ysios Capital

Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models

Read more

CVRx® Secures $113 Million in New Financing

by Ysios Capital

CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completi...

Read more

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...

Read more

Stat Diagnostica announces 25 Million Euros in Series C Financing led by Gilde Healthcare

by Ysios Capital

Led by new investor Gilde Healthcare , the financing round al so drew participation from existing investors , including Kurma Partners ; Ysios Capital ; Idinvest Partners ; Boehringer Ingelheim Ventur...

Read more

La Caixa leads an investment round in Inbiomotion with the participation of Ysios Capital

by Professional Newco

The fund is driven by ”la Caixa” and the Centro para el Desarrollo Tecnológico Industrial (Centre for Industrial Technological Development, CDTI) under the framework of the Innvierte Programme an...

Read more

Aelix Therapeutics completes Series A funding of € 11.5 M ($ 12.7 M)

by Caixa Capital Risc

The proceeds will support the development of the HTI immunogen as a therapeutic vaccine against HIV infection, up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individ...

Read more

Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)

by Ysios Capital

Ysios Capital, a Spanish investment fund, led the round. The fundraising was also supported by a substantial syndicate of new investors including Kurma Partners, Roche Venture Fund, Idinvest Partners ...

Read more
Subscribe to Directory
Write an Article

Highlight

Interview with Dámaso Molero, general m...

by 3P Biopharmaceuticals

Dámaso Molero: “There are great opportunities in Latin America for ...

The CNIO and Hospital 12 de Octubre find...

by CNIO - Centro Nacional de Investigaciones Oncológicas

Myelofibrosis is a very rare serious disease that affects bone marrow ...

Photos Stream